ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), for the treatment of first-line metastatic triple negative breast cancer (mTNBC).

被引：0
|
作者：
Ma, Fei
Qiu, Fuming
Tong, Zhongsheng
Shi, Yehui
Yu, Guohua
Wu, Xinhong
Wang, Hong
Wang, Jiani
Yang, Hua
Liu, Anwen
Zhang, Yan
Zheng, Hongmei
Lan, Qiongyu
Zhang, Yongqiang
Cheng, Ying
Zhou, Qing
Xing, Xiaoyan
Chen, Xiaomei
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[5] Weifang Med Univ, Weifang Peoples Hosp, Weifang, Peoples R China
[6] Weifang Med Univ, Affiliated Hosp 1, Weifang, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Breast Surg, Wuhan, Peoples R China
[8] Hubei Prov Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[9] Wuhan Clin Res Ctr Breast Canc, Wuhan, Peoples R China
[10] Nanchang Third Hosp, Nanchang, Jiangxi, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[12] Affiliated Hosp Hebei Univ, Baoding, Hebei, Peoples R China
[13] Nanchang Univ, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[14] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[15] Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Jiangxi, Peoples R China
[16] Beijing Hosp, Beijing, Peoples R China
[17] Jilin Canc Hosp, Changchun, Peoples R China
[18] Shanghai Escugen Biotechnol Co Ltd, Shanghai, Peoples R China
[19] Shanghai Escugen Biotechnol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13132
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    CANCER RESEARCH, 2023, 83 (08)
  • [42] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [43] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [44] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] High Expression of Trophoblast Cell Surface Antigen 2 in Triple-negative Breast Cancer Identifies a Novel Therapeutic Target
    Makhoul, Elias
    Dadmanesh, Farnaz
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 152 : S37 - S37
  • [46] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
    Altundag, Kadri
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan Saim
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
    Emens, Leisha A.
    Adams, Sylvia
    Loi, Sherene
    Schneeweiss, Andreas
    Rugo, Hope S.
    Winer, Eric P.
    Barrios, Carlos H.
    Dieras, Veronique
    de la Haba-Rodriguez, Juan
    Gianni, Luca
    Chui, Stephen Y.
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
    Yao, Sufei
    Shang, Chengzhang
    An, Gao
    Guo, Chaoshe
    An, W. Frk
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [49] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer Robinson
    Starodub, Alexander
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Ocean, Allyson J.
    Berlin, Jordan
    Messersmith, Wells A.
    Thomas, Sajeve Samuel
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Goldenberg, David M.
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
    Huang, Wenpeng
    Li, Liming
    Zhou, Yuhan
    Yang, Qi
    Mixdorf, Jason C.
    Barnhart, Todd E.
    Hsu, Jessica C.
    Saladin, Rachel J.
    Liu, Chihao
    Rosenkrans, Zachary T.
    Engle, Jonathan W.
    Gao, Jianbo
    Kang, Lei
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
12345